small nuclear ribonucleoprotein polypeptide C pseudogene 10Genealiases: []
Q-omics provides the consensus-scored SNRPCP10 profile across patient tissues and cancer cell-line models. SNRPCP10 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, SNRPCP10 is differentially expressed in 4, with the highest sampling consensus in HNSC. Additionally, SNRPCP10 RNA expression shows 5,670 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BRCA, HNSC, and STAD as cancer lineages where SNRPCP10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNRPCP10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNRPCP10 survival associations across molecular data types. SNRPCP10 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNRPCP10 RNA expression–survival associations across cancer types. High SNRPCP10 expression shows unfavorable associations in BRCA, LUSC, MESO and PCPG, but favorable associations in PAAD and LUAD. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify BRCA as the clearest survival context for SNRPCP10 RNA expression.
This table summarizes SNRPCP10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for SNRPCP10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNRPCP10 shows lower tumor expression in BRCA and LUSC and higher tumor expression in HNSC and STAD. The HNSC box plot shows higher SNRPCP10 RNA expression in tumor versus normal tissue (log2 FC = +0.081, t-test p = .013).
This table shows molecular features associated with SNRPCP10 in patient tissues and cancer cell lines. In patient samples, SNRPCP10 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
